Based on the TIMER method, we observed that NR2F6 expression was significantly associated with immune infiltration in 31 cancer types: B cells in 23 types of cancer, CD4 + T cells in 19 types of cancer, CD8 + T cells in 22 types of cancer, neutrophils in 22 types of cancer, macrophages in 20 types of cancer, and dendritic cells in 18 types of cancer. This evidence concerns the gene NR2F6 and cancer.